The state of Nevada currently has 5 active clinical trials seeking participants for Diabetic Macular Edema research studies. These trials are conducted in various cities, including Las Vegas, Henderson, Reno and Pahrump.
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Recruiting
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Retina Consultants of Nevada, Las Vegas, Nevada +1 locations
Conditions: Diabetic Macular Edema
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Sierra Eye Associates, Reno, Nevada
Conditions: Diabetic Macular Edema (DME)
Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-2)
Recruiting
The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/05/2024
Locations: Oculis Investigative Site - Sierra Eye Associates, Reno, Nevada
Conditions: Diabetic Macular Edema
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Recruiting
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding pa... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
12/05/2023
Locations: Reno, NV, Reno, Nevada
Conditions: Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
Recruiting
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: Assess the efficacy of foselutoclax compared to aflibercept Assess the safety and tolerability of foselutoclax
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Sierra Eye Associates, Reno, Nevada
Conditions: Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema